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Background: Couroupita guianensis Aubl. (Lecythidaceae) is commonly called Ayahuma and the Cannonball tree.
It is distributed in the tropical regions of northern South America and Southern Caribbean. It has several medicinal
properties. It is used to treat hypertension, tumours, pain, inflammatory processes, cold, stomach ache, skin diseases,
malaria, wounds and toothache.
Methods: The fruits of Couroupita guianensis were extracted with chloroform. Antimicrobial, antimycobacterial and
antibiofilm forming activities of the chloroform extract were investigated. Quantitative estimation of Indirubin, one
of the major constituent, was identified by HPLC.
Results: Chloroform extract showed good antimicrobial and antibiofilm forming activities; however it showed low
antimycobacterial activity. The zones of inhibition by chloroform extract ranged from 0 to 26 mm. Chloroform
extract showed effective antibiofilm activity against Pseudomonas aeruginosa starting from 2 mg/mL BIC, with 52%
inhibition of biofilm formation. When the chloroform extract was subjected to HPLC-DAD analysis, along with
Indirubin standard, in the same chromatographic conditions, it was found that Indirubin was one of the major
compounds in this plant (0.0918% dry weight basis).
Conclusions: The chloroform extract showed good antimicrobial and antibiofilm properties. Chloroform extract can
be evaluated further in drug development programmes.
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Couroupita guianensis Aubl. (Lecythidaceae) is commonly
called Ayahuma and the Cannonball tree. It is an ever-
green tree allied to the Brazil Nut (Bertholletia excelsa)
and is native to tropical northern South America and
the Southern Caribbean [1]. The trees are grown exten-
sively in Shiva temples in India. Hindus revere it as a
sacred tree because the petals of the flower resemble the
hood of the Naga, a sacred snake, protecting a Shiva
Lingam, the stigma. The tree also produces globular
brown woody, indehiscent, amphisarcun (double fleshy)* Correspondence: naif-al-dhabi@hotmail.com
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reproduction in any medium, provided the orfruits of an astonishing size, almost the size of a human
head [2]. It is widely planted in tropical and subtropical
botanical gardens as an ornamental; it does well under
cultivations and it is used to feed animals. Native
Amazonian people from Amazonian region and other
states of the north region of Brazil use infusions or
teas obtained from the leaves, flowers, and barks of
Couroupita guianensis to treat hypertension, tumours,
pain, and inflammatory processes [3]. The Cannonball
tree possesses antibiotic, antifungal, antiseptic and
analgesic qualities. The trees are used to cure cold and
stomach ache. Juice made from the leaves is used to
cure skin diseases, and shamans of South America have
even used tree parts for treating malaria. The inside of
the fruit can disinfect wounds and young leaves cure
toothache [4]. Chemical studies of this species showedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tryptanthrine, indigo, indirubin, isatin, linoleic acid,
carotenoids and sterols [5-10]. In the flowers, it was
possible to identify eugenol, linalool and (E,E)-farnesol
where as triterpenoid esters of fatty acids as β-amirin
palmitate were characterized in the leaves [11]. Indiru-
bin is a purple 3,20bisindole, and is a constituent of
indigo natural. Indigo natural is a dark blue powder
prepared from the leaves of a number of medicinal
plants including Baphicacanthus cusia (Acanthaceae),
Polygonum tinctorium (Polygonaceae), Isatis indigotica
(Brassicaceae), Indigofera suffrutticosa (Fabaceae) and
Indigofera tinctoria (Fabaceae) [12]. Indigo, naturally is
used in traditional Chinese medicine as a hemostatic,
antipyretic, antiinflammatory, and sedative agent in the
treatment of bacterial and viral infections [13]. In the
present communication we report the antimicrobial,
antimycobacterial and antibiofilm forming activities of
the chloroform extract of the fruit of C. guianensis.
The HPLC finger print of the chloroform extract




Fresh fruits of Couroupita guianensis were collected
during June 2011 from Loyola College Jesuit garden,
Chennai, India. The species was identified by a plant
taxonomist at Entomology Research Institute, Loyola
College, Chennai, India. A voucher specimen (No. ERI/
ETHPH/CQ/225) was deposited at the herbarium of the
institute.
Preparation of plant extract
The collected fruit was shade dried at room temperature
and powdered. 1 kg of fruit powder was extracted with
chloroform at room temperature for 48 hrs. The extract
was evaporated to dryness at 40°C under reduced
pressure.
Microbial organisms
The following Gram positive, Gram negative bacteria,
clinical isolates and fungi were used for the experiment.
Gram positive bacteria
Bacillus subtilis MTCC 441, Micrococcus luteus MTCC
106, Enterobacter aerogenesMTCC 111 and Staphylococcus
aureusMTCC 96.
Gram negative bacteria
Shigella flexneri MTCC 1457, Salmonella paratyphi-B,
Klebsiella pneumoniae MTCC 109, Pseudomonas
aeruginosa MTCC 741, Proteus vulgaris MTCC 1771
and Salmonella typhimurium MTCC 1251.Clinical isolates
Escherichia coli (ESBL-3984,), Escherichia coli (ESBL-
3904), Klebsiella pneumoniae (ESBL-3971), Klebsiella
pneumoniae (ESBL-75799), Klebsiella pneumoniae
(ESBL-3894), Klebsiella pneumoniae (ESBL-3967) and
Staphylococcus aureus (MRSA).
Fungi
Candida albicans MTCC 227 and Malassesia pachy-
dermatis; The reference cultures were obtained from
Institute of Microbial Technology (IMTECH), Chandigarh,
India-160 036 and Department of Microbiology, Christian
Medical College, Vellore, Tamil Nadu, India.
Preparation of inoculum
Bacterial inoculums were prepared by growing cells in
Mueller Hinton Broth (MHB) (Himedia, Mumbai) for
24 hrs at 37°C. Yeast was grown on Sabouraud Dextrose
Broth (SDB) (Himedia, Mumbai) at 28°C for 48 hrs.
Antibacterial activity
Antibacterial activity was carried out using disc diffusion
method [14]. Petri plates were prepared with 20 mL of
sterile Mueller Hinton Agar (MHA). The test cultures
were swabbed on the top of the solidified media and
allowed to dry for 10 min. A specific concentration
(5 mg/disc) of the chloroform extract was loaded to each
disc. The loaded discs were placed on the surface of the
medium. Negative control was prepared using respective
solvents. Streptomycin was used as positive control. The
plates were incubated for 24 hrs at 37°C for bacteria and
for 48 hrs at 28°C for fungi. Zones of inhibition were
recorded in millimetres and the experiment was repeated
twice.
Antimycobacterial assay
The anti-TB activity of chloroform extract was evaluated
against standard sensitive strain M. tuberculosis H37Rv
and rifampicin isolate M. tuberculosis XRD-1. The
mycobacterial cultures were obtained from Clinical
Microbiology Division, Indian Institute of Integrative
Medicine, Jammu 180 001, India. The minimum inhibi-
tory concentration (MIC) was determined using broth
micro-dilution assay [15,16]. The experiment was per-
formed in sterile Middlebrook 7H9 broth supplemented
with 10% ADC (BD Biosciences, USA). The above-
mentioned test bacteria were grown to mid-log phase
(10–12 days) at 37°C with shaking in the test media
(Middlebrook 7H9 broth supplemented with 10% ADC).
Stock solution (1 mg/mL) of chloroform extract was
prepared in DMSO and 6.4 μl volume of these stock
solutions were added to the wells of a 96 well U bottom
microtitre plates (Tarson, Mumbai, India) and nine 2
fold serial dilutions of the compound were prepared in
Table 1 Antimicrobial activity of the chloroform extract
of C. guianensis fruits (5 mg/mL)
Organism Chloroform extract Streptomycin
Gram positive
S. aureus 26 14
E. aerogens 19 22
M. luteus 18 26
B. subtilis 14 22
Gram negative
S. flexneri 20 30
P. vulgaris 12 30
S. paratyphi-B - 24
S. typhimurium - 18
P. aeruginosa 8 30
K. pneumonia 18 20
Clinical isolates
E. coli (ESBL-3984) 20 12
E. coli (ESBL-3904) 18 12
K. pneumoniae (ESBL-3971) 14 16
K. pneumoniae (ESBL-75799) 16 16
K. pneumoniae (ESBL-3894) 15 14
K. pneumoniae (ESBL-3967) 12 16
S. aureus (MRSA) 18 -
Fungi Ketoconazole
C. albicans 8 28
M. pachydermatis 16 26
(−) no activity; Streptomycin (standard antibacterial agent); Ketoconazole
(standard antifungal agent); Negative control (solvent) (Nil); N = 2.
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adjusted to be equivalent to 1 McFarland turbidity stand-
ard (~1 x 107 CFU/mL), which was further diluted to 1:10
in test media and a 100 μl volume of this diluted inoculum
was added to each well of the plate, resulting in a final
inoculum of 5 x 105 CFU/mL. The final concentrations of
the chloroform extract after the addition of inoculums ran-
ged from 0.12 to 32 μg/mL. Rifampicin in the concentra-
tion range from 0.12 to 32 μg/mL was used as control drug
in the experiment. Periphery wells of the plate were filled
with sterile distilled water to prevent evaporation of media
in the wells. The plates were incubated at 37°C under 5%
CO2 for 3 weeks. Inhibition of growth was determined
both by visual examination and with a spectrophotometer
at an OD600 (Multiskan spectrum; Thermo Scientific,
USA). The lowest concentration of the compound showing
no turbidity was recorded as MIC.
Effect of chloroform extract of C. guianensis on biofilm
formation
The effect of the Chloroform extract on biofilm forming
activity of P. aueroginosa was tested on 24-well polystyr-
ene plates. Chloroform extract at concentrations of
1–5 mg/mL were added in LB containing the bacterial
suspension at 106 CFUmL/1. The plates were incubated
for 24 h at 37°C. After incubation, biofilm was stained
with 0.4% crystal violet. The biofilm inhibitory concentra-
tion (BIC) was determined as the lowest concentration
that produced visible disruption in biofilm formation and
significant reduction in the readings when compared with
the control wells at OD570nm. Thus, the BIC was deter-
mined by both spectrophotometric quantification and also
by microscopic visualization. For visualization of biofilms
by light microscopy, the biofilms were allowed to grow on
glass pieces (1/1 cm) placed in 24-well polystyrene plates
supplemented with the extracts (1–5 mg/mL) and incu-
bated for 24 h at 37°C. Crystal violet staining was per-
formed as described above. Stained glass pieces were
placed on slides with the biofilm pointing up and were
inspected by light microscopy at magnifications of X40.
Visible biofilms were documented with an attached digital
camera (Nikon Eclipse Ti 100) [17].
Standardization of chloroform extract by HPLC-DAD
analysis
Sample (chloroform extract) (10 mg in 100 mL) and
standard Indirubin (5 mg in 100 mL) were dissolved in
methanol. The solutions were filtered through a mem-
brane filter (pore size 0.20 μm) prior to HPLC analysis.
HPLC analysis was carried out on a Waters Alliance
2695 separations Module with photodiode array detector
(Waters, 2996). The LC column was an YMC pack ODS A
(150 mm× 4.6 mm, 5 μm) column. Two mobile phases A
and B were used at flow rate of 1.0 mL/min. The mobilephase was filtered through a 0.45 μm filter, and degassed by
vacuum, followed by sonication. Mobile phase A consisted
of water with 0.1% orthophosphoric acid and mobile phase
was B acetonitrile. Separation was carried out at room
temperature. A gradient was used, starting at 95% A, chan-
ging to 10% A linearly in 15 min. After elution the column
was re-equilibrated for 3 min under the initial conditions.
The HPLC profile of C. guianensis chloroform extract was
compared with that of standard compound, Indirubin
which was best detected at 254 nm.
Statistics
Statistical analysis was performed using SPSS. Values
were expressed as mean ± SD. A Duncan–ANOVA test
was used to compare parameters between groups and a
Dunnett–ANOVA test to compare between tests and
control.
Results and discussion
In this communication we report the antimicrobial, anti-
mycobacterial and antibiofilm forming activities of the
Table 2 Minimum inhibitory concentration of the chloroform extract of C. guianensis against M. tuberculosis
Strains Lab code Chloroform extract MIC (μg/mL) Rifampicin (μg/mL)
M. tuberculosis H37Rv (HR-Sen) ATCC 27294 H37Rv >64 0.12
M. tuberculosis XRD-1 XRD >64 32
Negative control: Nil growth.
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extract of C. guianensis exhibited promising activity against
bacteria and fungi using disc diffusion method. The activity
of chloroform extract against bacteria and fungi are given
in Table 1. The compound showed appreciable activity
against Gram positive bacteria, B. subtilis (14 mm), M.
luteus (18 mm), E. aerogenes (19 mm) and S. aureus
(26 mm); Gram negative bacteria S. flexneri (20 mm), K.
pneumonia (18 mm), P. aeruginosa (8 mm) and P. vulgaris
(12 mm); Clinical isolates ESBL-3984 (20 mm), ESBL-3904
(18 mm), ESBL-3971 (14 mm), ESBL-75799 (16 mm),
ESBL-3894 (15 mm), ESBL-3967 (12 mm) and MRSA
(18 mm); Fungi C. albicans (8 mm) and M. pachydermatis
(16 mm). Compared to control, the chloroform extract of
C. guianensis showed moderate activity against tested bac-
teria and fungi. C. guianensis fruit was previously shown to
have good in vitro antibacterial activity in few human
pathogens [18,19]. Hence in this study we gave more
importance to clinical isolates. C. albicans which causesFigure 1 Microscopic visualization (x40) of antibiofilm activity of low
(A) 2.0 mg/mL, (B) 1.0 mg/mL, (C) control and (D) Negative control (Indcandidiasis is becoming an increasingly important species
worldwide, due to the fact that it is among the opportunis-
tic pathogens frequently found in AIDS patients [20]. The
chloroform extract of C. guianensis showed good activity
against C. albicans. The chloroform extract was inactive
against two strains of Mycobacterium tuberculosis at tested
concentration of 64 μg/mL, thus showing low activity as
compared with rifampicin (Table 2). As shown in Figure 1
and Table 3, the chloroform extract inhibited biofilm for-
mation against P. aueroginosa starting from 2.0 mg/mL
(BIC). Interestingly, the chloroform extract showed a pro-
nounced effect on inhibition of biofilm formation at low
concentrations. The chloroform extract showed effective
antibiofilm formation activity at 2.0 mg/mL (BIC), with
52% inhibition. The efficiency of the extract was also
confirmed by microscopic visualization. The antibiofilm
formation activity was low at higher concentration. This
indicated that the biofilm formation was possibly inhibited
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Figure 2 HPLC chromatograms of the chloroform extract of the fruit
Indirubin (B). Chloroform extract. Indirubin.
Table 3 BIC of chloroform extract against the biofilm form-
ing activity of Pseudomonas aeruginosa strain at 24 h
S.No Chloroform extract(mg/ml) Antibioflim activity
1 5.0 0.546 ± 0.00145
2 4.0 0.581 ± 0.00176
3 3.0 0.637 ± 0.00644
4 2.0 0.712 ± 0.00318
5 1.0 0.941 ± 0.00260
6 Control 1.706 ± 0.00240
Effect of chloroform extract on biofilm formation of Pseudomonas aeruginosa strain
as quantified by crystal violet staining and measuring A570nm. Mean values of
triplicate independent experiments and SD are shown (N = 3) (Negative control-Nil).
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have interfered with the adherence of P. aueroginosa by
releasing the adhesion compound lipoteichoic acid from
the streptococcal cell surface [21]. P. aeruginosa has
emerged as one of the most problematic Gram-negative
pathogen, with an alarmingly high antibiotic resistance rate
[22,23]. The activity of C. guianensis might be due to its
ability to complex with cell wall [19] and thus inhibiting
the microbial growth [24]. An important step in biofilm
development is the formation of the characteristic biofilm
architecture [25]. Cell surface charge and CSH play a
crucial role in bacterium–host cell interactions [26]. There
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Gram-positive bacteria [28-30]. Biofilm-associated diseases
caused by Gram-positive bacteria include caries, gingivitis,
periodontitis, endocarditis and prostatitis [31]. Many forms
of streptococcal infections, especially recurrent and chronic
infections, are associated with the formation of bacterial
biofilms [32]. This phenomenon is also observed in antibio-
tics where the sub-inhibitory concentrations (sub-MICs) of
antibiotics, although not able to kill bacteria, can modify
their physicochemical characteristics and the architecture
of their outermost surface and may interfere with some
bacterial functions.
When the chloroform extract was subjected to HPLC-
DAD analysis, along with Indirubin standard, in the
same chromatographic conditions, it was found that
Indirubin was one of the major compounds in this plant.
The retention time of the standard compound with UV
detection at 254 nm was about 13.4 min. The UV spec-
tral similarity was also confirmed by the overlay of the
UV spectrum of the standard to the corresponding peak
of chloroform extract of the fruit of C. guianensis,
extracted from PDA detection. The HPLC chromato-
gram of the chloroform extract with that of standard
Indirubin is given in Figure 2 and the overlay UV
spectrum of the Indirubin standard to the corresponding
peak of chloroform extract of the fruit of C. guianensis is
given in Figure 3. The above HPLC quantification
showed that the Indirubin content of the fruits of C.
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Figure 3 UV spectrum overlay of Indirubin standard and the correspo
guianensis. The retention time of the standard compound with UV detect
confirmed by the overlay of the UV spectrum of the standard to the corres
extracted from PDA detection.has been used as antibacterial and antifungal agent, particu-
larly, to cure fungal diseases, dermatophytic and skin lesion
diseases [33]. Indirubin, a natural purple pigment, occurs as
3, 20-bisindole; it has been shown to be active for the treat-
ment of chronic myelocytic leukemia [13]. While parent
indirubin molecule is derived from the non-enzymatic and
spontaneous dimerization of colorless precursors, isatin
and indoxyl, in the indigo-producing plants, a series of
novel derivatives, have been synthesized by various molecu-
lar substitution of the parental indirubin backbone with
improved solubility, selectivity and bioavailability [34-37].
Indirubin derivatives have been shown to inhibit cyclin-
dependent kinases (CDKs), glycogen synthase kinase
(GSK)-3 and activate aryl hydrocarbon receptor (AhR).
Anticancer activity of indirubin in human cancer cells,
such as MCF-7, HBL-100 breast cancer cells, HT-29
colon adenocarcinoma, haematopoietic cell lines Jurkat,
and A498, CAKI-1, AKI-2 renal cancer cells [12,37-40]
have been reported. Indirubin could also suppress autop-
hosphorylation of fibroblast growth factor receptor
(FGFR)-1 but stimulate extracellular signal regulated kin-
ase (ERK1/2) activity through p38 mitogen-activated pro-
tein kinase [41].
Conclusion
The chloroform extract of the fruit of C. guianensis
showed good antimicrobial activities but low antimyco-
bacterial activity against tested strains. The antibiofilm
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ion at 254 nm was about 13.4 min. The UV spectral similarity was also
ponding peak of chloroform extract of the fruit of C. guianensis,
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low concentrations with 52% inhibition.
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